Total
0
Shares
Amplia Therapeutics - CEO and MD, John Lambert
CEO and MD, John Lambert
Source: Amplia Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial in first-line pancreatic cancer patients
  • The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients
  • In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy
  • Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022
  • Amplia Therapeutics closed down 2.50 per cent at 19.5 cents

Amplia Therapeutics (ATX) has completed the design for a Phase 2 clinical trial in first-line pancreatic cancer patients.

The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with gemcitabine and nabpaclitaxel – the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients.

In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy.

The company said conducting the phase 2 clinical trial in first-line patients is expected to expedite recruitment and provide the best opportunity to detect any efficacy signal from the addition of AMP945 to chemotherapy.

“Clinical evaluation of AMP945 as part of a first-line treatment for pancreatic cancer significantly de-risks the program and makes the drug relevant for a much larger patient base.” said Dr John Lambert, CEO of Amplia Therapeutics.

 “If we are able to see positive signs that AMP945 improves the leading current treatment option we will commence discussions with regulators and potential partners concerning future trials required to support product approval.”

Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022, which is expected to take around 18 to 24 months.

Amplia Therapeutics closed down 2.50 per cent at 19.5 cents.

ATX by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.